BioTime, Inc. (NYSE MKT: BTX) announced that its subsidiary Asterias
Biotherapeutics, Inc. (OTCBB: ASTY) has reached an agreement with Cancer
Research UK and Cancer Research Technology (CRT), the charity’s
development and commercialization arm, to conduct a clinical
trial of Asterias’ novel immunotherapy treatment AST-VAC2 in subjects
with non-small cell lung cancer.
for BioTime Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology Partner for Clinical Trial of Immunotherapy Vaccine for Lung Cancer investment picks